## Audited Group financial results and cash dividend declaration for the year ended 30 June 2022





									O	
1	n		v .	<b>~</b>	$\sim$			+ 1		
1		ш			u	u		u	u	
				_	•	•	_	٠.	_	

The Board of Directors (Board) is very pleased to report a strong operational and financial performance, driven by improved demand for its over-the-counter (OTC) and consumer healthcare products.

The Group has achieved healthy growth in turnover, which with some benefit from the exchange rate and an advantageous sales mix, has yielded an exceptional increase in trading profit and excellent cash generation.

## Dividend

The Board has declared a final dividend of 109 cents per share for the year ended 30 June 2022 out of income reserves, bringing the total dividend for the year to 213 cents, an increase of 25% over the prior year and in line with the growth in earnings.

## Prospects

Given the ongoing weakness in the local economy, high fuel prices and the significant deterioration of the Rand, much of our focus for 2023 will be on management of margins. Consumers are likely to remain under pressure because of rising food, transport and energy costs.

We remain cautious, but we are confident in the resilience of our balanced portfolio of healthcare brands, with a proven ability to adapt to changing market dynamics.

	Cha	ange %	Audited 2022	Audited 2021	
Revenue	(R'000)	12	8 705 817	7 776 854	
Gross profit	(R'000)	14	3 057 755	2 682 775	
Trading profit	(R'000)	22	1 112 287	914 610	
Operating profit	(R'000)	24	1 052 820	849 755	
Headline earnings per share	(cents)	24	502.0	404.7	
Basic earnings per share	(cents)	25	494.8	396.3	
Total assets Net asset value per share Interim dividend declared per share Final dividend declared per share	(R'000) (cents) (cents) (cents)		7 889 162 3 242.4 104.0 109.0	7 040 418 2 894.7 80.0 90.0	
Segment revenue Consumer OTC Prescription Hospital	(R'000)	23	1 562 727	1 267 287	
	(R'000)	19	2 059 258	1 735 239	
	(R'000)	7	3 228 242	3 021 520	
	(R'000)	6	1 855 035	1 752 229	
Segment trading profit Consumer OTC Prescription Hospital	(R'000)	49	351 144	235 380	
	(R'000)	9	318 080	292 327	
	(R'000)	24	276 451	223 826	
	(R'000)	2	164 350	161 385	

## Dividend distribution

The Board has declared a final gross dividend out of income reserves of 109 cents per share in respect of the year ended 30 June 2022. The South African dividend tax ("DT") rate is 20% and the net dividend payable to shareholders who are not exempt from DT is 87.20 cents per share. Adcock Ingram currently has 169 758 861 ordinary shares in issue and qualifying for ordinary dividends. The income tax reference number is 9528/919/15/3.

The salient dates for the distribution are detailed below:

Last date to trade *cum* distribution Tuesday, 13 September 2022 Shares trade *ex* distribution Wednesday, 14 September 2022

Record date Friday, 16 September 2022
Payment date Monday, 19 September 2022

Share certificates may not be dematerialised or rematerialised between Wednesday, 14 September 2022 and Friday, 16 September 2022, both dates inclusive.

N Madisa AG Hall
Chairperson Chief Executive Officer

Approved by the Board: 24 August 2022

SENS release date: 25 August 2022

Addock Ingram Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 2007/016236/06) Share code: AIP ISIN: ZAE000123436 ("Adcock Ingram" or "the Company" or "the Group") Company secretary M Phalafala Registered office 1 New Road, Midrand, 1682 Postal address Private Bag X69, Bryanston, 2021 Transfer secretaries Computershare Investor Services Proprietary Limited, Rosebank Towers, 15 Biermann Avenue, Rosebank, Johannesburg, 2196. Private Bag X9000, Saxonwold, 2132 Auditors PricewaterhouseCoopers Inc, 4 Lisbon Lane, Waterfall, 2090 Sponsor Rand Merchant Bank (a division of FirstRand Bank Limited), 1 Merchant Place, corner Fredman Drive and Rivonia Road, Sandton, 2196. Investec Bank Limited, 100 Grayston Drive, Sandton, 2146.